investor_presentation
CareDx
Loading viewer...
investor_presentation
Format: PDF investor_presentation
Incyte announced the acquisition of Escient Pharmaceuticals on April 23, 2024. The transaction adds EP262 and EP547 candidates to Incyte's pipeline, targeting atopic dermatitis, chronic inducible urticaria, and chronic urticaria. This acquisition strengthens Incyte's inflammation and autoimmunity portfolio.
earnings
21 Pages
investor_presentation
29 Pages
Trex Company
Sunrise Communications UPC Switzerland Acquisition 2019
investor_presentationinvestor_presentation
8 Pages
Sunrise Communications Group AG
Balaxi Pharmaceuticals Investor Presentation: IPR-Driven Pharma
investor_presentationinvestor_presentation
20 Pages
Balaxi Pharmaceuticals Limited
investor_presentation
CareDx